Epizyme Inc. (EPZM:NASDAQ) -- Placeholder sh
Trending Company

(6/27/22)

aaa

ddd

Gene Therapy Co. Releases Data From Huntington's Study
Source: Streetwise Reports (06/23/2022)

Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial
Source: Streetwise Reports (06/22/2022)

Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.

Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.

Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.

The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.